Business Overview: LifeMD, Inc. (NASDAQ: LFMD)

---

Executive Summary

LifeMD is a New York-based, direct-to-patient telehealth and pharmacy company offering virtual primary care, weight management, men's health, women's health, and behavioral health services. The company runs a vertically integrated model combining its own technology platform, an affiliated provider network licensed across all 50 states, a wholly-owned pharmacy in Lancaster, Pennsylvania, and AI-enabled operations — giving it more control over fulfillment than telehealth competitors that rely entirely on third-party pharmacies.

LifeMD matters because it has built meaningful scale in the fast-growing direct-to-consumer telehealth category, with approximately 328,000 active patient subscribers as of December 31, 2025, and roughly 95% of revenue coming from recurring subscriptions. The company sold its WorkSimpli software business in November 2025 to focus entirely on telehealth and pharmacy, and began accepting insurance in June 2024 (covering roughly 112 million lives at year-end 2025, with a target of 230 million by mid-2026) — a structural differentiator from cash-pay-only peers. FY2025 revenue grew 25% to $194.1 million, with the net loss from continuing operations narrowing from $23.2 million to $10.2 million.

---

1. Core Business Model & How They Work

LifeMD's model is a vertically integrated, subscription-based direct-to-patient telehealth and pharmacy pipeline.

 Patient online         Affiliated licensed            LifeMD-owned pharmacy        Recurring
 intake/visit        →  provider network           →   (Lancaster, PA)          →   subscription
 request                (50-state affiliated            fulfillment & shipping        renewal
                         physicians/NPs; virtual                                      (~95% of
                         visit + diagnosis)                                            revenue)
                                 │
                                 ▼
                    B2B/partner integrations: Eli Lilly (Zepbound),
                    Novo Nordisk (Wegovy/Ozempic), Medifast, Ash
                    Wellness, Withings, ASCEND (EstroGel)

Patients access care through LifeMD's platform, are seen by an affiliated provider, and — where a prescription is appropriate — have it filled through LifeMD's own pharmacy rather than a third-party, giving the company more control over cost, margin, and the patient experience. Roughly 95% of revenue is recurring subscription revenue, and the June 2024 move into insurance acceptance has materially expanded the addressable patient base beyond pure cash-pay telehealth.

---

2. Product Portfolio (Key Offerings)

---

3. Competitive Landscape

• Hims & Hers Health — the closest direct comparable, offering broad telehealth plus in-house pharmacy fulfillment, but at substantially larger scale and marketing spend; Hims & Hers represents LifeMD's most significant head-to-head competitive threat.
• Ro (Roman/Rory) — a privately-held direct-to-consumer telehealth competitor spanning men's and women's health, competing for similar GLP-1 and condition-specific patient demand.
• Teladoc Health — larger and more enterprise/insurance-focused, competing at the margins where LifeMD's insurance-acceptance expansion increasingly overlaps with Teladoc's traditional base.
• Drugstore chains and mass merchandisers (CVS, Walgreens, Walmart) — increasingly building their own telehealth and weight-management distribution, which could bypass independent telehealth platforms like LifeMD.
• Branded drug manufacturers going direct — Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare pharmacy) are both current LifeMD partners and emerging potential disintermediators, selling GLP-1 drugs directly to consumers in ways that could reduce reliance on telehealth intermediaries over time.

LifeMD's relative position is as a mid-scale, vertically integrated specialist competing against a much larger direct peer (Hims & Hers) and facing a long-term structural risk that its own pharma partners could eventually sell around it.

---

4. Strategic Strengths & Risks

Strengths:

• Vertically integrated owned pharmacy, giving LifeMD more control over fulfillment economics and patient experience than telehealth platforms dependent on third-party pharmacies.
• Early insurance-acceptance pivot (since June 2024), a real differentiator from cash-pay-only competitors and a structural driver of the addressable patient base (112 million covered lives at year-end 2025, targeting 230 million by mid-2026).
• Diversified, multi-brand reach (LifeMD, RexMD, ShapiroMD) across weight management, men's health, women's health, and behavioral health reduces single-category dependence.
• Improving profitability trajectory — net loss from continuing operations narrowed from $23.2 million to $10.2 million even as revenue grew 25%, with adjusted EBITDA of roughly $19.8 million for the first nine months of 2025.

Risks:

• Intense, better-funded competition. Hims & Hers in particular has substantially greater scale and marketing budgets, and the industry is explicitly described in LifeMD's own filing as featuring "fierce competition."
• Direct-to-consumer disintermediation risk. Eli Lilly and Novo Nordisk — currently partners — are both building their own direct-to-consumer pharmacy channels (LillyDirect, NovoCare), which could reduce the need for telehealth intermediaries like LifeMD over time.
• Disclosed internal control weaknesses. LifeMD's 10-K discloses "current and potential material weaknesses" in internal controls and references a prior error correction to previously issued financial statements — a real governance and accounting risk flag investors should weigh.
• Legal/regulatory exposure in GLP-1 telehealth. The filing references Novo Nordisk litigation against unnamed telehealth firms, signaling broader legal risk around compounded and telehealth-distributed GLP-1 products.
• New government price-comparison competition. A federal online drug-pricing platform launched in February 2026 adds a new source of price transparency and competitive pressure.

---

5. Financial Overview

---

6. Summary Conclusion

LifeMD has built a genuinely differentiated position in direct-to-consumer telehealth through vertical integration — owning its pharmacy rather than outsourcing fulfillment — and an early move into insurance acceptance that has materially expanded its addressable market, all while narrowing losses as revenue grew 25% in FY2025. That said, the company operates in a fiercely competitive, well-funded category dominated at the top by Hims & Hers, and its reliance on partnerships with Eli Lilly and Novo Nordisk for GLP-1 drug access carries a genuine long-term risk: those same manufacturers are simultaneously building their own direct-to-consumer channels that could eventually bypass telehealth intermediaries altogether. Combined with disclosed internal-control weaknesses in its own financial reporting, LifeMD's forward story depends on converting its vertical-integration and insurance-access advantages into durable profitability before larger, better-capitalized competitors and its own pharma partners narrow that window.